Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:01:32 2026-06-29 pm EDT			After hours 08:00:00 pm
1,229.93 ^USD	+1.81%		1,229.00	-0.08%

01:59am	An exuberant quarter for equities, but not an irrational one?
01:36am	Innovent Biologics, Inc. and Eli Lilly and Company Enter Commercialization Agreement for Verzenios (Abemaciclib) in Mainland China	CI

Health Care Down on Cyclical Bias - Health Care Roundup

Published on 04/16/2026 at 05:09 pm EDT

Dow Jones

ELI LILLY AND COMPANY

+1.81%

ABBOTT LABORATORIES

-1.50%

Health-care companies fell as traders rotated into cyclical sectors, betting on an extension to the U.S.-Iran cease-fire.

Abbott Laboratories shares fell after the maker of baby-food, adult nutrition and other medical products cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.

Eli Lilly's late-stage clinical trial of a type 2 diabetes treatments showed promise.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-16-26 1708ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	ELI LILLY AND COMPANY	1,229.93USD	+1.81%	+11.60%	1,097B
	ABBOTT LABORATORIES	92.71USD	-1.50%	+5.56%	161B

Latest news about Eli Lilly and Company

01:59am	An exuberant quarter for equities, but not an irrational one?
01:36am	Innovent Biologics, Inc. and Eli Lilly and Company Enter Commercialization Agreement for Verzenios (Abemaciclib) in Mainland China	CI
Jun. 29	Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program	MT
Jun. 29	Lilly, Regeneron selected for US program to review new manufacturing plants faster	RE
Jun. 29	FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports	RE
Jun. 29	Eli Lilly, Abu Dhabi's Health Department Enter MoU to Manage Obesity, Alzheimer's Disease	MT
Jun. 29	Emirati Shares End Lower as US-Iran Exchange Fresh Strikes	MT
Jun. 29	FDA set to review Sandoz's generic GLP-1s	RE
Jun. 29	Sandoz's Applications for Mounjaro, Zepbound Generics Accepted for FDA Review	DJ
Jun. 29	Sandoz New Drug Applications for Generic Tirzepatide Versions Accepted for US FDA Review	MT
Jun. 29	Pfizer, Innovent GLP-1 drugs clear China insurance hurdle	RE
Jun. 26	Health Care Up on Rotation Into Laggards -- Health Care Roundup	DJ
Jun. 26	Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy	CI
Jun. 26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
Jun. 26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company